Clinical Quiz: Pharmacotherapy Recommendations from ESC/EAS 2019 Dyslipidemia Guidelines

The management of dyslipidemia has experienced significant changes in recent decades driven by advances in understanding pathophysiology as well as developments in pharmacological therapies. All this advancement has made guideline recommendations a critical component of educating clinicians.

For decades, statins were not only the centerpiece, but often the only option for many patients who struggled with lipid disorders. While their role as a mainstay in therapy has persisted through time as a result of their affordability, efficacy, and established safety profile, the advent of new therapies has redefined what is considered to be an optimal approach to management of dyslipidemia for many patients.

In this clinical quiz, we test your knowledge of pharmacotherapy recommendations from the 2019 European Society of Cardiology/European Atherosclerosis Society Guidelines for the Management of Dyslipidaemias: Lipid Modification to Reduce Cardiovascular Risk.

What is the first-line pharmacological treatment for lowering LDL-C according to the guidelines?

Quizzes in this series:

Quiz 1: Lipid Management Principles from 2019 ESC/EAS Guidelines on Dyslipidemia

Quiz 2: Risk Assessment and Stratification from 2019 ESC/EAS Guidelines on Dyslipidemia

Quiz 3: Pharmacotherapy Recommendations from ESC/EAS 2019 Dyslipidemia Guidelines

Quiz 4: Lifestyle and Nonpharmacological Interventions from ESC/EAS 2019 Dyslipidemia Guidelines

Reference:

1. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk [published correction appears in Eur Heart J. 2020 Nov 21;41(44):4255. doi: 10.1093/eurheartj/ehz826]. Eur Heart J. 2020;41(1):111-188. doi:10.1093/eurheartj/ehz455

Editor’s note: this quiz was composed with the assistance of artificial intelligence tools.